Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Allory

Showing results (81-90 of 230) with videos related to

Pageof 23
Sort By:
European Urology|August 2, 2011
The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillanceGuillaume Ploussard, Alexandre de la Taille, Younes Bayoud, et al.
Bulletin Du Cancer|March 11, 2023
[Collecting duct carcinoma and renal medullary carcinoma in the age of new therapies]Zoé Guillaume, Yves Allory, Edouard Auclin, et al.
Urologic Oncology|July 2, 2011
Evaluation of combined oncologic and functional outcomes after robotic-assisted laparoscopic extraperitoneal radical prostatectomy: trifecta rate of achieving continence, potency and cancer controlEvanguelos Xylinas, Xavier Durand, Guillaume Ploussard, et al.
Journal of Proteome Research|March 14, 2017
Large-Scale SRM Screen of Urothelial Bladder Cancer Candidate Biomarkers in UrineElodie Duriez, Christophe D Masselon, Cédric Mesmin, et al.
World Journal of Urology|July 3, 2014
Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason ≤ 6 on biopsy coresThomas Seisen, Françoise Roudot-Thoraval, Pierre Olivier Bosset, et al.
BJU International|November 6, 2010
Low pretreatment total testosterone (< 3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancerEvanguelos Xylinas, Guillaume Ploussard, Xavier Durand, et al.
World Journal of Urology|November 26, 2010
Impact of the primary Gleason pattern on biochemical recurrence-free survival after radical prostatectomy: a single-center cohort of 1,248 patients with Gleason 7 tumorsOlivier Alenda, Guillaume Ploussard, Pascal Mouracade, et al.
BJU International|August 27, 2004
Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancerDimitri Vordos, Bernard Paule, Francis Vacherot, et al.
BJU International|May 27, 2009
Predicting tumour location in radical prostatectomy specimens: same-patient comparisons of 21-sample versus sextant biopsyKevin De Laet, Alexandre de la Taille, Guillaume Ploussard, et al.
BJU International|May 12, 2010
The effect of prostate-specific antigen screening during the last decade: development of clinicopathological variables independently of the biopsy core numberGuillaume Ploussard, Vidal Azancot, Nathalie Nicolaiew, et al.
Pageof 23

Showing results (81-90 of 230) with videos related to

Sort By:
Pageof 23
European Urology|August 2, 2011
The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillanceGuillaume Ploussard, Alexandre de la Taille, Younes Bayoud, et al.
Bulletin Du Cancer|March 11, 2023
[Collecting duct carcinoma and renal medullary carcinoma in the age of new therapies]Zoé Guillaume, Yves Allory, Edouard Auclin, et al.
Urologic Oncology|July 2, 2011
Evaluation of combined oncologic and functional outcomes after robotic-assisted laparoscopic extraperitoneal radical prostatectomy: trifecta rate of achieving continence, potency and cancer controlEvanguelos Xylinas, Xavier Durand, Guillaume Ploussard, et al.
Journal of Proteome Research|March 14, 2017
Large-Scale SRM Screen of Urothelial Bladder Cancer Candidate Biomarkers in UrineElodie Duriez, Christophe D Masselon, Cédric Mesmin, et al.
World Journal of Urology|July 3, 2014
Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason ≤ 6 on biopsy coresThomas Seisen, Françoise Roudot-Thoraval, Pierre Olivier Bosset, et al.
BJU International|November 6, 2010
Low pretreatment total testosterone (< 3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancerEvanguelos Xylinas, Guillaume Ploussard, Xavier Durand, et al.
World Journal of Urology|November 26, 2010
Impact of the primary Gleason pattern on biochemical recurrence-free survival after radical prostatectomy: a single-center cohort of 1,248 patients with Gleason 7 tumorsOlivier Alenda, Guillaume Ploussard, Pascal Mouracade, et al.
BJU International|August 27, 2004
Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancerDimitri Vordos, Bernard Paule, Francis Vacherot, et al.
BJU International|May 27, 2009
Predicting tumour location in radical prostatectomy specimens: same-patient comparisons of 21-sample versus sextant biopsyKevin De Laet, Alexandre de la Taille, Guillaume Ploussard, et al.
BJU International|May 12, 2010
The effect of prostate-specific antigen screening during the last decade: development of clinicopathological variables independently of the biopsy core numberGuillaume Ploussard, Vidal Azancot, Nathalie Nicolaiew, et al.
Pageof 23